TY - JOUR
T1 - Site-Randomized Controlled Trial of a Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression Among Youth Living With HIV in the United States
AU - The IMPAACT 2002 team
AU - Brown, Larry K.
AU - Chernoff, Miriam
AU - Kennard, Betsy D.
AU - Emslie, Graham J.
AU - Lypen, Kathryn
AU - Buisson, Sarah
AU - Weinberg, Adriana
AU - Whiteley, Laura B.
AU - Traite, Shirley
AU - Krotje, Chelsea
AU - Harriff, Lauren
AU - Townley, Ellen
AU - Bunch, Amber
AU - Purswani, Murli
AU - Shaw, Ray
AU - Spector, Stephen A.
AU - Agwu, Allison
AU - Shapiro, David E.
N1 - Funding Information:
Supported by the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT). Overall support for IMPAACT has been provided by the National Institute of Allergy and Infectious Diseases (NIAID) with cofunding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH); all components of the National Institutes of Health (NIH); under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC), and UM1AI106716 (IMPAACT LC); and by NICHD contract number HHSN275201800001I. Support for this project was also provided by the Providence/Boston Center for AIDS Research, a NIH-funded program (P30 AI042853). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Publisher Copyright:
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2021/12/15
Y1 - 2021/12/15
N2 - Background:Depression is frequent among youth living with HIV (YLWH). Studies suggest that manualized treatment guided by symptom measurement is more efficacious than usual care.Setting:This study evaluated manualized, measurement-guided depression treatment among YLWH, aged 12-24 years at 13 US sites of the International Maternal Pediatric Adolescent AIDS Clinical Trials Network.Methods:Using restricted randomization, sites were assigned to either a 24-week, combination cognitive behavioral therapy and medication management algorithm (COMB-R) tailored for YLWH or to enhanced standard of care, which provided standard psychotherapy and medication management. Eligibility included diagnosis of nonpsychotic depression and current depressive symptoms. Arm comparisons used t tests on site-level means.Results:Thirteen sites enrolled 156 YLWH, with a median of 13 participants per site (range 2-16). At baseline, there were no significant differences between arms on demographic factors, severity of depression, or HIV status. The average site-level participant characteristics were as follows: mean age of 21 years, 45% male, 61% Black, and 53% acquired HIV through perinatal transmission. At week 24, youth at COMB-R sites, compared with enhanced standard of care sites, reported significantly fewer depressive symptoms on the Quick Inventory for Depression Symptomatology Self-Report (QIDS-SR score 6.7 vs. 10.6, P = 0.01) and a greater proportion in remission (QIDS-SR score ≤ 5; 47.9% vs. 17.0%, P = 0.01). The site mean HIV viral load and CD4 T-cell level were not significantly different between arms at week 24.Conclusions:A manualized, measurement-guided psychotherapy and medication management algorithm tailored for YLWH significantly reduced depressive symptoms compared with standard care at HIV clinics.
AB - Background:Depression is frequent among youth living with HIV (YLWH). Studies suggest that manualized treatment guided by symptom measurement is more efficacious than usual care.Setting:This study evaluated manualized, measurement-guided depression treatment among YLWH, aged 12-24 years at 13 US sites of the International Maternal Pediatric Adolescent AIDS Clinical Trials Network.Methods:Using restricted randomization, sites were assigned to either a 24-week, combination cognitive behavioral therapy and medication management algorithm (COMB-R) tailored for YLWH or to enhanced standard of care, which provided standard psychotherapy and medication management. Eligibility included diagnosis of nonpsychotic depression and current depressive symptoms. Arm comparisons used t tests on site-level means.Results:Thirteen sites enrolled 156 YLWH, with a median of 13 participants per site (range 2-16). At baseline, there were no significant differences between arms on demographic factors, severity of depression, or HIV status. The average site-level participant characteristics were as follows: mean age of 21 years, 45% male, 61% Black, and 53% acquired HIV through perinatal transmission. At week 24, youth at COMB-R sites, compared with enhanced standard of care sites, reported significantly fewer depressive symptoms on the Quick Inventory for Depression Symptomatology Self-Report (QIDS-SR score 6.7 vs. 10.6, P = 0.01) and a greater proportion in remission (QIDS-SR score ≤ 5; 47.9% vs. 17.0%, P = 0.01). The site mean HIV viral load and CD4 T-cell level were not significantly different between arms at week 24.Conclusions:A manualized, measurement-guided psychotherapy and medication management algorithm tailored for YLWH significantly reduced depressive symptoms compared with standard care at HIV clinics.
KW - adolescents
KW - antidepressants
KW - cognitive behavioral therapy
KW - human immunodeficiency virus
KW - major depressive disorder
UR - http://www.scopus.com/inward/record.url?scp=85123879032&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123879032&partnerID=8YFLogxK
U2 - 10.1097/QAI.0000000000002790
DO - 10.1097/QAI.0000000000002790
M3 - Article
C2 - 34483297
AN - SCOPUS:85123879032
SN - 1525-4135
VL - 88
SP - 497
EP - 505
JO - Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
JF - Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
IS - 5
ER -